Brokerages Set Janux Therapeutics, Inc. (NASDAQ:JANX) Target Price at $88.00

Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) have been assigned a consensus rating of “Buy” from the thirteen analysts that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $88.00.

A number of analysts recently weighed in on the company. Scotiabank decreased their price objective on Janux Therapeutics from $62.00 to $41.00 and set a “sector perform” rating for the company in a report on Friday, February 28th. Leerink Partners increased their price objective on Janux Therapeutics from $79.00 to $91.00 and gave the company an “outperform” rating in a report on Tuesday, December 3rd. William Blair reiterated an “outperform” rating on shares of Janux Therapeutics in a report on Friday, January 10th. Lifesci Capital upgraded Janux Therapeutics to a “strong-buy” rating in a report on Friday, December 27th. Finally, HC Wainwright reiterated a “buy” rating and set a $70.00 price target on shares of Janux Therapeutics in a report on Monday, March 3rd.

Insider Transactions at Janux Therapeutics

In related news, Director Ra Capital Management, L.P. acquired 341,742 shares of the business’s stock in a transaction dated Wednesday, March 5th. The shares were bought at an average price of $30.64 per share, with a total value of $10,470,974.88. Following the transaction, the director now directly owns 9,658,988 shares of the company’s stock, valued at $295,951,392.32. This trade represents a 3.67 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Andrew Hollman Meyer sold 13,334 shares of the firm’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $54.88, for a total transaction of $731,769.92. Following the completion of the transaction, the insider now directly owns 82,139 shares in the company, valued at approximately $4,507,788.32. The trade was a 13.97 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 50,002 shares of company stock valued at $2,684,703 in the last 90 days. 29.40% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Janux Therapeutics

Large investors have recently added to or reduced their stakes in the business. Russell Investments Group Ltd. lifted its position in Janux Therapeutics by 77.7% in the 4th quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company’s stock valued at $54,000 after acquiring an additional 442 shares in the last quarter. GF Fund Management CO. LTD. bought a new position in Janux Therapeutics in the 4th quarter valued at about $59,000. Plato Investment Management Ltd lifted its position in Janux Therapeutics by 18.7% in the 3rd quarter. Plato Investment Management Ltd now owns 1,186 shares of the company’s stock valued at $54,000 after acquiring an additional 187 shares in the last quarter. Avanza Fonder AB bought a new position in Janux Therapeutics in the 4th quarter valued at about $139,000. Finally, Meeder Asset Management Inc. bought a new position in Janux Therapeutics in the 4th quarter valued at about $159,000. Institutional investors own 75.39% of the company’s stock.

Janux Therapeutics Stock Down 0.4 %

NASDAQ JANX opened at $30.64 on Thursday. The company has a market capitalization of $1.81 billion, a price-to-earnings ratio of -26.19 and a beta of 3.23. Janux Therapeutics has a twelve month low of $29.63 and a twelve month high of $71.71. The stock has a fifty day simple moving average of $41.27 and a 200 day simple moving average of $47.48.

Janux Therapeutics (NASDAQ:JANX) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.36) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.13. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. Research analysts expect that Janux Therapeutics will post -1.38 earnings per share for the current fiscal year.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.